Biomedical subjects

Paolo Buja

Publications and source records attributed to Paolo Buja.

4 recordsLinked to original sources

PubMed2006

Clinical outcome of patients undergoing low aggressive angioplasty combined with brachytherapy and short-term dual antiplatelet therapy for in-stent restenosis.

OBJECTIVE: The impact of vessel injury on the outcome of patients undergoing percutaneous coronary intervention combined with brachytherapy for in-stent restenosis is under investigation. We report our clinical experience adopting a low aggressive balloon angioplasty technique, to limit vessel trauma, associated with brachytherapy and short-term dual antiplatelet therapy. METHODS: Forty-nine consecutive patients, undergoing percutaneous coronary intervention with brachytherapy for symptomatic in-stent restenosis, were prospectively observed for a median time of 21 + or - 8 months. Clinical follow-up included anginal status, death, myocardial infarction and repeat revascularization; only patients with evidence of ischaemia repeated coronary angiography. Low aggressive angioplasty consisted in the use of a conventional balloon with a balloon to artery ratio < or = 1, avoiding high inflation pressures and the use of other devices. Dual antiplatelet therapy was continued for 3-6 months. RESULTS: Early angiographic result was good and the need for additional stent implantation was low (3.9%). At follow-up, we did not observe death, acute myocardial infarction or stent thrombosis, but 10 patients repeated coronary angiography for recurrence of ischaemia: disease progression was present in two cases (4.1%). Restenosis emerged in the remaining eight patients (16.3%): two cases showed restenosis within the target lesion segment, one case within the injured segment, one case within the radiated segment, and four cases at the edges. The consequent new revascularization was surgical in three patients and percutaneous in seven patients. CONCLUSIONS: Our data suggest that low aggressive angioplasty followed by brachytherapy and short-term dual antiplatelet therapy for in-stent restenosis is related to a good outcome, with a low restenosis rate and without stent thrombosis.

Aged↗

PubMed2005

Moderate-to-severe ischemic mitral regurgitation and multivessel coronary artery disease: Impact of different treatment on survival and rehospitalization.

BACKGROUND: The outcome of moderate-to-severe ischemic mitral regurgitation with multivessel coronary artery disease is still debated. We analysed the effect of different treatments, i.e. medical therapy (MT), coronary artery by-pass grafting (CABG) alone and CABG with mitral valve surgery (MVS), on the survival and rehospitalization of these patients. METHODS: Between 1990 and 2002, we identified 111 consecutive patients, aged 73+/-8 years, with chronic moderate-to-severe mitral regurgitation and multivessel coronary artery disease at cardiac catheterization, in absence of primary valve disease. Twenty-two patients were treated by MT, 50 by CABG and 39 by CABG+MVS. Overall, the median clinical and echocardiographic follow-ups were 34.9 and 14.6 months, respectively. RESULTS: Groups differed significantly (p < 0.03) for left ventricular end-diastolic volume index (MT 153+/-54, CABG 125+/-35, CABG + MVS 129+/-38, ml/m2), ejection fraction (MT 35+/-14, CABG 38+/-13, CABG + MVS 50+/-14, %) and mammary artery graft use (CABG 60, CABG + MVS 74, %). While in-hospital mortality was higher in surgical patients (MT 13.6, CABG 18, CABG + MVS 17.9, %, p=0.09), 7-years mortality showed a trend in favour of CABG + MVS compared to other groups (MT 100, CABG 57, CABG + MVS 29, %, p = 0.1). After adjusting for baseline differences, CABG alone or with MVS had a 57% (HR 0.43, p = 0.005) and 53% (HR 0.47, p = 0.02) risk reduction of combined cardiac death and rehospitalization rate compared to MT. However, only CABG + MVS independently predicted mortality (risk reduction 65%, HR 0.35, p = 0.027). CONCLUSIONS: In moderate-to-severe ischemic mitral regurgitation and multivessel coronary artery disease, surgery reduced total cardiac events but only a concomitant MVS significantly improved survival.

Aged↗

PubMed2004

Time delay-adjusted survival benefit of angioplasty over thrombolysis in acute myocardial infarction: influence of time from symptom onset.

BACKGROUND: The time-to-treatment is a critical determinant of outcome after acute myocardial infarction. We investigated the relationship between the primary angioplasty (PCI)-related time delay and the benefit of PCI over thrombolytic therapy (TT), considering the time elapsing from symptom onset in 21 randomized trials comparing PCI to TT. METHODS: PCI-related time delay was calculated as the median of the "door-to-balloon" time minus the median of the "door-to-needle" time. The survival benefit was defined as the difference between 30-day mortality after TT and after PCI. The relationships between time delay and benefit were assessed by linear regression. RESULTS: PCI-related time delay ranged from 7 to 104 min. Linear regression showed that at a PCI-related delay of 75 min, PCI and TT yielded equivalent reductions in mortality (p = 0.03). When the trials with the longest and shortest delays were excluded, the benefit of PCI over TT was nullified after a delay of 62 min, and every additional 10-min delay produced a 1.1% increase in mortality (p = 0.01). When trials with a symptom duration < 6 hours (median 130 min) were considered, PCI-related delay still correlated with an absolute risk reduction in 30-day mortality with a time to equipoise of 57 min (p = 0.03). Lack of correlation (p = 0.85) was observed in trials enrolling patients within 12 hours of symptom onset (median 185 min). CONCLUSIONS: Our analysis suggests that PCI-related delay substantially modifies the benefit of PCI over TT, particularly in case of patients presenting early following symptom onset.

Angioplasty↗

PubMed2003

Aortic valve replacement in severe aortic stenosis with left ventricular dysfunction: determinants of cardiac mortality and ventricular function recovery.

OBJECTIVE: The influence of left ventricular (LV) dysfunction on survival of patients with severe aortic stenosis is poorly characterized. Few data are available about preoperative predictors of cardiac mortality and LV function recovery after aortic valve replacement of such patients. The aim of our study was to examine the outcome and the preoperative predictors of postoperative cardiac death and of LV function recovery in these patients. METHODS: We evaluated 85 consecutive patients with severe aortic stenosis (aortic valve area <1 cm(2)) and severe depression of LV ejection fraction (EF) <35% at cardiac catheterization. Among them, 52 underwent aortic valve replacement and they were compared to patients who were not operated on. All patients had a mean clinical follow-up of 53 months and 94% of them had a mean echocardiographic follow-up of 14 months after aortic valve replacement. RESULTS: The mean baseline characteristics included: LVEF 28+/-6%, peak-to-peak transvalvular gradient 51+/-29 mmHg, aortic valve area 0.63+/-0.25 cm(2). Thirty-three patients did not undergo aortic valve replacement: 32 of them died within 3 years. Fifty-two patients underwent aortic valve replacement and 16 had a concomitant coronary bypass surgery. In-hospital mortality was 8%. Postoperative NYHA functional class changed from 2.84+/-0.67 to 1.43+/-0.44 (P<0.001) and LVEF from 29+/-6% to 43+/-10% (P<0.001). At follow-up 10 patients died of heart disease. By multivariate analysis, preoperative LV end-systolic volume index (ESVI) was the only covariate of cardiac death (LVESVI/10 ml/m(2), OR 1.3, CI 1.1-1.8, P<0.028). By using a receiver operating characteristic curve, LVESVI< or =90 ml/m(2) was the best cut-off value (sensitivity and specificity 78%) to fit with a better survival (93% vs. 63%, P<0.01) and with LVEF recovery after aortic valve replacement (EF improved by 15+/-10% vs. 8+/-5%, P<0.001). CONCLUSIONS: Despite LV dysfunction, aortic valve replacement appears to change drastically the natural history of severe aortic stenosis. Preoperative LV levels predict different postoperative survival rate and LVEF recovery.

Adult↗